What is the intrinsic value of CTX.TO?
As of 2025-12-29, the Intrinsic Value of Crescita Therapeutics Inc (CTX.TO) is
0.12 CAD. This CTX.TO valuation is based on the model Peter Lynch Fair Value.
With the current market price of 0.47 CAD, the upside of Crescita Therapeutics Inc is
-73.59%.
Is CTX.TO undervalued or overvalued?
Based on its market price of 0.47 CAD and our intrinsic valuation, Crescita Therapeutics Inc (CTX.TO) is overvalued by 73.59%.
CTX.TO Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(26.64) - (1.27) |
(2.60) |
-659.2% |
| DCF (Growth 10y) |
(1.13) - (21.15) |
(2.18) |
-569.6% |
| DCF (EBITDA 5y) |
0.01 - (0.13) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(0.21) - (0.29) |
(1,234.50) |
-123450.0% |
| Fair Value |
0.12 - 0.12 |
0.12 |
-73.59% |
| P/E |
0.19 - 0.28 |
0.23 |
-49.8% |
| EV/EBITDA |
0.50 - 0.97 |
0.58 |
24.9% |
| EPV |
1.46 - 1.93 |
1.70 |
264.7% |
| DDM - Stable |
0.36 - 4.82 |
2.59 |
456.7% |
| DDM - Multi |
(0.72) - (7.55) |
(1.31) |
-381.5% |
CTX.TO Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
8.65 |
| Beta |
-0.13 |
| Outstanding shares (mil) |
18.61 |
| Enterprise Value (mil) |
0.83 |
| Market risk premium |
5.10% |
| Cost of Equity |
6.61% |
| Cost of Debt |
5.07% |
| WACC |
6.36% |